At a compound annual growth rate (CAGR) of 4.2% from 2023 to 2033, the global diamond-blackfan anemia (DBAAASE) syndrome therapeutics market is expected to surpass an amazing US$ 4.8 billion in 2023. By 2033, the market for therapeutics for Diamond-Blackfan Anaemia (DBAAASE) Syndrome is anticipated to be worth US$ 7.29 billion.
Due to the fact that 90% of infected people experience hematologic problems in the first year of birth, the global market for diamond-blackfan anaemia treatments has experienced explosive growth in recent years. In addition, it is projected that shifting lifestyles, escalating government R&D funding, and quickly advancing technology would boost market expansion over the forecast period.
The diamond-blackfan anaemia syndrome therapeutics market is dominated by North America due to the existence of significant important stakeholders, high disposable income, rising healthcare expenses, and a developed medical industry in this area. 25% of persons with DBA pass away before the age of 50 from associated medical conditions, according to a report released by Clevel and Clinic, the DBA Registry of North America, a database that contains information on people who have this ailment.
Get Sample Copy of Latest Reports! https://www.futuremarketinsights.com/reports/sample/rep-gb-16433
DBA UK is a registered charity (1083179) that is governed by a written constitution and run by appointed volunteer groups. They offer support, research, and hope to the DBA community by bringing families together to discuss their experiences, share the most recent health history, and raise funds to assist those with DBA in the United Kingdom.
Key Takeaways from the Market Study:
- Global DBAAASE syndrome therapeutics market to expand 1.5x from 2023 to 2033
- By treatment, blood transfusions to experience a growth rate of 6.9%
- Around 2 out of 5 DBAAASE syndrome therapeutics to happen across North America
- Europe to emerge as an important contributor, expected to surge at a CAGR of 3.7%
- Treatment through corticosteroids to gain equal traction as blood transfusions
“As medical science expands, treatments and therapies for a broad range of blood disorders is gaining major traction. This is boding well for the market on diamond blackfan anemia syndrome, with healthcare providers introducing a plethora of therapies and treatment approaches,” says an FMI analyst.
Reach Out To Our Analyst For Prompt Assistance With Your Questions! https://www.futuremarketinsights.com/ask-question/rep-gb-16433
Key Market Players
Key players in the Diamond–Blackfan Anemia (DBA)/Aase Syndrome Therapeutics market are
- Sumitomo Corporation
- Johnson & Johnson Private Limited
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Merck & Co. Inc.
- LEO Pharma A/S
- Cipla Limited
- GSK Plc.
- AstraZeneca Plc.
- Abbott Laboratories
- Bayer AG
Recent Development:
In July 2021, AstraZeneca procured Alexion Pharmaceuticals, a global biotech company. With this acquisition, the company will be able to enter the market for rare disease medicines, ushering in a new chapter. Moreover, the acquisition strengthened AstraZeneca’s scientific presence in immunology and would allow the company to continue to pioneer the discovery and development of medicines for patients with rare diseases using Alexion’s new complement-biology system and robust pipeline.
In June 2022, Pfizer will collaborate with Sirana Pharma, a biotechnology company. The collaboration would help Pfizer recognize and validate a novel therapeutic concept for unique and severe bone diseases.
Revolutionizing Customer Engagement: Learn from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16433
Key Segments Profiled in the Diamond–Blackfan Anemia (DBAAASE) Syndrome Therapeutics Industry Survey:
By Treatment:
- Corticosteroids
- Chelation Therapy
- Blood Transfusions
- Stem Cell Transplant
- Others
By End User:
- Hospitals
- Clinics
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
